Catalyst Brief

← Calendar

Readoutin 76d

Novartis Pharmaceuticals — everolimus

Phase 3 primary completion: Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment.

Date
Feb 2027
Type
Readout
Indication
Tuberous Sclerosis Complex

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Novartis Pharmaceuticals

  1. May2027
  2. Apr2027
  3. Mar2027